Investor Relations

We are a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. We improve compliance, absorption, and more with our proprietary drug delivery technology.

H.C. Wainwright 23rd Annual Global Investment Conference
 Monday, September 13, 2021
 7:00am - 8:00am EDT